Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial compares fenebrutinib to ocrelizumab in adults with primary progressive multiple sclerosis; the study status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Fenebrutinib (Fenebrutinib)
• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis, Primary Progressive | Phase 3 | Status: ACTIVE_NOT_RECRUITING